August 9, 2010 - Health care professionals will attend a conference devoted to the fundamentals of establishing and developing a cooling program and features Minneapolis physicians and other national experts,

Miracle on Ice: Therapeutic Hypothermia for Cardiac Arrest Patients conference will take place September 9 to 10, in Minneapolis, Minn.

August 9, 2010 - Researchers at Mayo Clinic are working to reduce radiation dosages used to acquire perfusion and other CT images.

August 9, 2010 – Enrollment was recently completed in a clinical trial of Medtronic’s Complete SE (self-expanding) vascular stent for the treatment of atherosclerosis in the superficial femoral artery (SFA), including the proximal popliteal artery (PPA).

August 9, 2010 – According to Millennium Research Group (MRG), a medical technology market research company, Invatec has traditionally held a much stronger position in the European percutaneous transluminal angioplasty (PTA) balloon catheter market compared to the United States.

August 9, 2010 – A merger is being finalized between Medtronic and cardiac surgery device maker ATS Medical. The company develops and manufactures products and services for the treatment of structural heart disease and the ablation of cardiac arrhythmias.

ATS Medical expects the closing of the merger will take place on or about Aug. 12.

August 4, 2010 — A second-generation of the Diamondback Predator 360 peripheral arterial disease (PAD) system features improvements in the crowns and shaft for enhanced clinical performance and shorter procedure times. The U.S. Food and Drug Administration (FDA) recently granted Cardiovascular Systems Inc. (CSI) special 510(k) marketing clearance for the device.

August 4, 2010 — When Beaumont Hospital physicians recently held a heart screening for high school students, they found some surprising results. Of the 402 students screened, 34 students were advised to continue with sports and follow-up with their personal physicians and an additional five students were instructed to stop exercise until fully evaluated.

August 4, 2010 — In recent years, concerns have been raised both inside and outside of the U.S. Food and Drug Administration (FDA) about whether the current 510(k) program achieves its goals of making safe and effective devices available to the public while fostering innovation.

August 3, 2010 — Patient enrollment began in the EVOLVE clinical trial, which is designed to assess the safety and performance of the Boston Scientific Synergy Coronary Stent (previously referred to as the Evolution stent). It uses a bioabsorbable polymer and everolimus drug formulation to create a thin, uniform coating confined to the outer surface of the stent.

August 3, 2010 — Patients have the right to refuse or request the withdrawal of any unwanted medical treatment. In an article published in the online issue of Mayo Clinic Proceedings, investigators explore the legal and ethical permissibility of carrying out such a request specific to a ventricular assist device (VAD).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now